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EDITORIAL
Smoking and dialysis: A dreadful scenario for the
cardiovascular system?
Although the cardiac death rate of dialysis patients has but with the exclusion of all patients 15 years of age
decreased significantly over the past three decades, car- (N 99) and a shorter follow-up time of 9 to 12 months,
diovascular morbidity still accounts for approximately one revealed that smoking independently increased the like-
half of the deaths among adults undergoing chronic dial- lihood of having coronary artery disease by 22% as com-
ysis. Compared to age- and gender-matched cohorts from pared with nonsmokers [3]. This implicates that smoking
the general population, cardiac death is up to 20 times would indeed increase the risk of myocardial infarction.
more frequent in dialysis patients. Thus, this nonrenal In favor of this assumption, smoking was shown to be a
comorbid condition is the major determinant of the fate risk factor for atherosclerotic cardiovascular accidents
of patients on renal replacement therapy. Against this during a follow-up of 9 years in a prospective study,
background it is amazing that smoking, the most impor- including 147 patients with predialysis chronic renal fail-
tant modifiable cardiovascular risk factor, has been treated ure [4]. It is noteworthy, however, that in a cross-sec-
like the Cinderella of dialysis research. This may be due to tional analysis of 936 hemodialysis patients enrolled in
the fact that some earlier reports had found no association the baseline phase of the hemodialysis study (HEMO),
between smoking and the risk of developing cardiovascu- smoking was not significantly associated with coronary
lar complications in hemodialysis patients [1]. artery disease [5]. In contrast, smoking was associated
In this issue of Kidney International, Foley, Herzog, with cerebrovascular disease (odds ratio 1.68; P 0.008)
and Collins [2] present data from the United States Renal and peripheral vascular disease (odds ratio 1.74; P 
Data System (USRDS) Wave 2 Study, which address 0.003). The latter confirms the finding of Foley, Herzog,
the possible impact of smoking on cardiovascular out- and Collins [2] and others [6].
comes in dialysis patients. Wave 2, a substudy of the Dial- The observation of an increased risk of new-onset
ysis Morbidity and Mortality Study (DMMS) prospec-
congestive heart failure in smokers on dialysis confirms
tively follows a group of patients who initiated their
earlier reports. Smoking had previously been shown todialysis therapy during 1996 and 1997. The smoking sta-
be a risk factor for systolic dysfunction [7] and to be onetus of the 4024 patients in the study was obtained at the
of the most significant independent predictors for low-initial data collection 60 days after the initiation of chronic
output left ventricular failure in end-stage renal diseasedialysis (hemodialysis or continuous ambulatory perito-
(ESRD) [8].neal dialysis). New-onset cardiovascular events and death
The shorter survival of smokers as compared withafter the initiation of dialysis were identified with the
nonsmokers observed in the study of Foley, Herzog, andhelp of the USRDS identification numbers from Medi-
Collins [2] is of particular concern. Others had previouslycare claims records over a mean follow-up period of
reported the same association. In a prospective studyabout 2 years.
[9], lifelong smoking level was significantly higher in 10The major finding of the study is that active smoking
out of 57 hemodialysis patients who died during a follow-at study inception was associated with increased rates of
up of nearly 3 years. In another prospective study, includ-new-onset congestive heart failure, new-onset peripheral
ing 188 hemodialysis patients, smoking was significantlyvascular disease, and shorter patient survival. This find-
more frequent in the deceased group after a follow-uping persisted after adjustment for baseline age, demogra-
of 30 months [10]. Smoking is a risk factor for deathphy, comorbidity, and mode of dialysis therapy. In con-
during the first 90 days of dialysis [7]. Conversely, long-trast, former smokers had adjusted event risks similar
term ESRD survivors are characterized by a very lowto those who had never smoked.
prevalence of active smokers [11]. The risk seems toThe fact that smoking did not predispose to acute
be excessively high for dialysis patients with diabetescoronary syndromes or stroke in this study may be due to
an insufficient follow-up time. Interestingly, an analysis mellitus, where cigarette smoking at the start of renal
using the same DMMS Wave 2 data set of 4024 patients, replacement therapy leads to a particularly deleterious
outcome (relative risk of mortality 2.28; P  0.05) [12].
Lower serum albumin concentrations predict increased
mortality in hemodialysis patients. Baseline serum albu- 2003 by the International Society of Nephrology
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min is significantly lower in active as compared to non- together with the finding of the current study that the
status of former smoker was not related to any negativesmokers on hemodialysis [7].
The limitations of the study design of Foley, Herzog, effect on cardiovascular disease and mortality, leads to
the conclusion that there is probably no harm done, whenand Collins [2] are obvious and mainly discussed by the
authors. The results are weakened by the fact that some we take a nonevidence-based approach and convince our
patients on renal replacement therapy to stop smokingconfounders were not addressed (e.g., residual renal
function, which is protective against mortality even after even before controlled data from interventional trials are
available to prove a potential benefit of this intervention.adjustment for smoking and other cardiovascular risk
factors [13]). A major limitation is that the authors did
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